Fangfang Liu

机构：Jiangxi University of Traditional Chinese Medicine, Chinese Academy of Sciences, Shenzhen Sixth People's Hospital, Shanghai Advanced Research Institute, Anshan Hospital, Bayer (Germany) · ORCID：0000-0002-9527-1131

发表论文 92 篇 · 总被引 1392 次 · h-index 22

代表论文

• Integrins in cancer: Emerging mechanisms and therapeutic opportunities (2023 · Pharmacology & Therapeutics · 被引 184)
• Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform (2024 · Journal of Clinical Medicine · 被引 16)
• USP18 promotes the proliferation, invasion, and migration of head and neck squamous cell carcinoma by deubiquitinating PLK1 (2024 · Experimental Cell Research · 被引 12)
• Elongation factor 2 in cancer: a promising therapeutic target in protein translation (2024 · Cellular & Molecular Biology Letters · 被引 11)
• NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway (2023 · Cellular and Molecular Life Sciences · 被引 11)
• FOUNTAIN: a modular research platform for integrated real-world evidence generation (2024 · BMC Medical Research Methodology · 被引 10)